NASDAQ$ALT

Altimmune Inc · Q1 2017 earnings

Q1 2017 earnings · · Investor relations

Headline financials

Total Revenue

$804K

Previous: $1.01M-20.0%
EPS (adj)

-$9.53

Previous: -$0.67-1329.6%
Net Income

-$2.2M

Previous: -$1.23M-79.1%
Operating Income

-$3.18M

Previous: -$1.25M-153.8%
Gross Profit

-$1.98M

No prior period
R&D Expense

$726K

No prior period

Revenue & EPS history

Altimmune · Revenue · Quarterly

$804K

Q1 2017-20%vs Q1 2016
Beat estimate in 4 of 5 quarters(80%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

+2.4%

Avg return

Earnings day

+1.5%

Avg return

5 days after

+5.6%

Avg return

30 days after

60%

21 / 35 earnings

Positive

+35.0%

Q2 2022

Best reaction

-25.1%

Q3 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025———
Q1 2026-2.0%-8.8%-15.3%
Q4 2025-17.6%-9.6%-21.8%
Q3 2025+5.1%+14.1%+39.7%
Q1 2025-4.2%-7.2%+19.0%
Q4 2024+8.1%+0.3%-10.4%
Q3 2024+29.5%+3.5%+16.9%
Q2 2024+12.2%+14.7%+12.7%
Q1 2024+0.8%+9.2%-9.8%
Q4 2023+17.7%+18.3%-16.1%
Q3 2023+1.1%-6.4%+146.4%
Q2 2023+2.0%-4.7%-16.9%
Q1 2023+2.2%-6.6%-19.7%
Q4 2022+1.9%-2.0%-64.3%
Q3 2022+10.3%+12.7%+4.2%
Q2 2022+35.0%+37.3%+55.4%
Q1 2022+31.0%+34.3%+117.0%
Q4 2021+2.2%+12.1%-18.7%
Q3 2021-0.5%+1.3%-12.3%
Q2 2021+6.6%+14.9%+56.8%
Q1 2021+5.2%+4.7%+23.0%
Q4 2020-18.6%-19.5%-29.3%
Q3 2020-25.1%-18.6%-1.1%
Q2 2020-13.5%-5.5%-54.3%
Q1 2020+21.4%+21.6%+103.8%
Q4 2019-7.1%-6.5%-2.8%
Q3 2019-8.0%-10.9%-1.7%
Q2 2019-6.5%-6.5%-0.9%
Q1 2019+2.7%-4.7%-3.5%
Q4 2018+3.4%+6.6%-0.7%
Q3 2018-6.8%-9.1%-31.5%
Q2 2018+4.9%+0.3%-21.0%
Q1 2018+10.8%-1.9%+1.7%
Q4 2017-8.3%-5.9%-36.0%
Q3 2017-1.0%-7.1%-25.1%
Q2 2017-10.3%-12.0%+11.6%
Q1 2017———
Q4 2016———
Q3 2016———
Q2 2016———
Q1 2016———
Q4 2015———
Q3 2015———
Q2 2015———
Q1 2015———
Q4 2014———
Q3 2014———
Q2 2014———
Q1 2014———
Q4 2012———
Q4 2013———
Q3 2013———
Q2 2013———
Q1 2013———
Q3 2012———
Q2 2012———
Q1 2011———
Q1 2012———
Q4 2011———
Q3 2011———
Q2 2011———
Q4 2010———
Q3 2010———
Q2 2010———
Q1 2010———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro